West Pharma (WST) Tops Q3 EPS by 1c; Trims FY Rev Outlook, Announces $100M Stock Buyback

West Pharma (NYSE: WST) reported Q3 EPS of $0.44, $0.01 better than the analyst estimate of $0.43. Revenue for the quarter came in at $355.9 million versus the consensus estimate of $356.08 million.

West Pharma sees FY2014 EPS of $1.77-$1.82, versus the consensus of $1.82. West Pharma sees FY2014 revenue of $1.41-1.435 billion, versus prior guidance of $1.43-1.46 billion and the consensus of $1.44 billion.

In addition, the Company announced a $100 million share repurchase program.

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• Wells Fargo cuts Netflix rating on engagement risk, weak slate
• Is the S&P 500 in an "earnings bubble"? Goldman weighs in
• Brinker sets revenue and unit growth targets through fiscal 2029